Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Eupraxia Pharmaceuticals
Company

Eupraxia Pharmaceuticals

Tracked across 1 events · 7 articles · First seen Feb 19, 2026 · Last active Feb 20, 2026

Sentiment
70
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
Eupraxia Pharmaceuticals Completes $63.2M Public Offering
Eupraxia Pharmaceuticals successfully completed a public offering, raising approximately $63.2 million. This financing will significantly expand its pipeline, advance EP-104GI for eosinophilic esophagitis, and support commercial readiness. The company's stock has seen a 128% return over the past year, and analysts have set price targets suggesting confidence in its prospects.
Feb 19, 2026 · 7 articles
Relationships (1)
James Helliwell CEO ↔ Eupraxia Pharmaceuticals James Helliwell is the CEO of Eupraxia Pharmaceuticals, leading its strategic in
NEWSDESK
Track Eupraxia Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.